Neutral
●
GlobeNewsWire
●
vor 6 Monaten
EMERYVILLE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced the appointment of veteran commercial leader Nadia Dac as Chief Commercial Officer, effective May 4.